Media ReleasesImugene Limited

View All Imugene Limited News

Imugene announces Updated Phase Ib HER-Vaxx data

SYDNEY, Australia, 4 June 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cancer vaccine was presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting in Chicago Illinois, USA 31 May to 3 June 2019.

The abstract (number 4030) was presented by Dr Yee Chao, Director of the Department of Oncology at the Veterans General Hospital in Taipei, Taiwan and a lead investigator in the Phase 1b study and was featured at the ASCO Gastrointestinal (Noncolorectal) Cancer Session on Monday 3 June between 8:00am and 11:00am.

For Further information please download the attached PDF:
Download this document